AptarGroup reports Q1 2026 results on May 6 with the stock sitting close to technically oversold levels — and short sellers quietly building positions ahead of the release.
The most distinctive pre-earnings signal here is on the technical side. The 14-day RSI has dropped to 33, within reach of oversold territory, after the stock shed 4.3% over the past month to close at $120.60. The one-week decline of 3.3% is notably steeper than most correlated peers — AMCR fell 3.1% over the same period, AVY dropped just 1.5%, and GEF actually gained 0.5%. ATR has been the laggard in its peer group. Options positioning shows no particular alarm: the put/call ratio is 0.56, essentially flat with its 20-day average of 0.56, and the z-score is near zero. Borrow conditions are similarly relaxed — cost to borrow is a negligible 0.46%, and availability is ample, pointing to no meaningful pressure in the lending market.
Short sellers have been adding, but the scale is modest. SI edged up to 2.3% of the free float, rising roughly 19% over the past month in share terms — though from a low base, and still well under 3%. Days to cover is just 1.2. This is not a heavily contested stock; the uptick in shorts looks more like routine hedging than a conviction short thesis.
Where the real tension sits is in the debate over AptarGroup's transition story. Bulls point to the AMS Solutions segment, which has been compounding revenue at roughly 10% annually and now represents around 11% of Pharma revenue. Injectable products — driven by GLP-1 demand and the broader biologics shift — are growing at a 9% CAGR, and the bull case is that this momentum eventually lifts margins and rerates the multiple. Bears counter that the transition to a majority Pharma-focused company is moving slowly, and that currency exposure, trade tensions, and IP risks add noise to an already complicated margin story. Wells Fargo, the most active analyst on the name, moved to Overweight in March after cutting to Equal-Weight in January, then raised its target again on May 4 to $145 — still well below the analyst consensus mean near $163. At $120.60, the stock offers roughly 37% upside to that consensus target, though the wide dispersion in targets (Keybanc initiated at $220 last September, now a stale outlier) reflects genuine disagreement about the pace of earnings recovery. The trailing P/E near 110x on a quarterly basis warrants a note of caution — that figure reflects a soft normalised earnings quarter rather than a structural premium, with EV/EBITDA running closer to 10x on an annualised basis.
The Q1 print will test whether Pharma-led volume growth is enough to offset currency drag and margin pressure — and whether the recent underperformance versus packaging peers reflects company-specific concerns or simply sector rotation.
See the live data behind this article on ORTEX.
Open ATR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
